
Register to Join Webinar
Navigating Neurotoxicity: Strategies for Safer Drug Discovery and Development
A thorough screening of potential neurotoxic hazards is essential for the development of safe and efficient therapies, and this is crucial in contemporary drug discovery. Many promising drug candidates can be removed from target therapeutics due to neurotoxicity. Most of the time due to unforeseen adverse effects causes expensive drug failure and delays clinical trials as well. This webinar will delve into innovative approaches and solutions for risk mitigation during drug discovery process as it dives into the complexities of neurotoxicity.
We will discuss about most recent developments in predictive neurotoxicity models, including in vitro models, organoids and computational tools. These tools are revolutionizing the early detection of neurotoxic effects. Additionally, case study will be highlighted how these tools have been successfully included in drug development paradigm. Webinar will also address the regulatory requirements for global standards to ensure safety and efficacy of novel therapeutics.
Join us to navigate the complexities of neurotoxicity and empower your drug discovery process with more safe and effective tools.
Key Highlights of the Webinar:
- Understanding neurotoxicity: Mechanisms and implications in drug discovery.
- Early detection of neurotoxic effects using advanced in vitro and in silico models.
- Application of organoids and brain-on-a-chip systems in predicting neurotoxicity.
- Regulatory requirements and guidelines for assessing neurotoxicity.
- Case studies of drugs withdrawn due to neurotoxic effects and lessons learned.
- Future directions: AI/ML integration in neurotoxicity prediction and mitigation.
Biosketch of Speaker
Dr. Swati Chitrangi, PhD, Head of Production at Advancells Group, will be leading the session. With over 15 years of experience in regenerative medicine, stem cell therapy, and organoid research, Dr. Swati has contributed significantly to the advancement of disease modelling and drug discovery using organoids. Her deep expertise in precision medicine and patient-specific organoid development will provide valuable insights into the transformative potential of these advanced models.
Dr. Swati holds a PhD in Bioengineering and an MBA in Strategic Management from the Indian Institute of Management (IIML-2025), providing her with a unique blend of scientific and business acumen. She has been involved in several pioneering research projects and has authored publications on patient-derived organoids for precision oncology, the derivation of human iPSC lines, and engineered 3D in vitro models for drug toxicity studies. Her work emphasizes the translation of cutting-edge stem cell technology into practical applications for patient care and drug development.